TRAIL Sensitization of PC3 Prostate Cancer Cells by Doxorubicin Can Be Blocked by the Antioxidant N-Acetyl-Cysteine or by the Iron Chelator Deferoxamine

    October 2006 in “ Clinical Cancer Research ”
    Shai J. White, Laura M. Kasman, Laura Spruill … Christina Voelkel‐Johnson
    Studysummary This study found that doxorubicin-induced oxidative stress downregulates FLIPs and phosphorylates EF2, sensitizing prostate cancer cells to TRAIL; antioxidants may reduce doxorubicin's effectiveness, warranting further investigation.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on clincancerres.aacrjournals.org →
    Discuss this study in the Community →